Free Trial

CME Group (CME) Stock Forecast & Price Target

CME Group logo
$235.99 +0.07 (+0.03%)
(As of 12/17/2024 ET)

CME Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
4
Hold
7
Buy
4

Based on 15 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 4 have given a sell rating, 7 have given a hold rating, and 4 have given a buy rating for CME.

Consensus Price Target

$226.20
-4.15% Downside
According to the 15 analysts' twelve-month price targets for CME Group, the average price target is $226.20. The highest price target for CME is $258.00, while the lowest price target for CME is $180.00. The average price target represents a forecasted downside of -4.15% from the current price of $235.99.
Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

Sign Up

CME Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
4 Sell rating(s)
4 Sell rating(s)
4 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$226.20$224.47$209.73$220.00
Forecasted Upside-4.15% Downside-1.36% Downside-2.34% Downside3.31% Upside
Consensus Rating
Hold
Hold
Reduce
Moderate Buy

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CME Group Stock vs. The Competition

TypeCME GroupFinance CompaniesS&P 500
Consensus Rating Score
2.00
2.49
2.51
Consensus RatingHoldHoldModerate Buy
Predicted Upside-4.15% Downside13.18% Upside12.03% Upside
News Sentiment Rating
Positive News

See Recent CME News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/9/2024Barclays
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$231.00 ➝ $257.00+7.36%
11/11/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Lower TargetHold ➝ Hold$227.00 ➝ $226.00-0.14%
10/28/2024Piper Sandler
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$240.00 ➝ $250.00+10.55%
10/24/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$245.00 ➝ $258.00+12.64%
10/24/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Sabadra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$235.00 ➝ $235.00+2.60%
10/24/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$250.00 ➝ $255.00+12.12%
10/17/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$210.00 ➝ $233.00+2.02%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Clinch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$244.00+10.04%
10/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$195.00 ➝ $198.00-11.89%
10/3/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$177.00 ➝ $180.00-19.49%
9/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Katz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$221.00+1.60%
7/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$187.00 ➝ $191.00-3.65%
7/25/2024Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$212.00 ➝ $213.00+7.98%
4/25/2024Rosenblatt Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell ➝ Sell$185.00 ➝ $187.00-12.04%
3/6/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$225.00 ➝ $245.00+12.27%
2/7/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$192.00 ➝ $198.00+13.30%
1/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$226.00 ➝ $220.00+29.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:48 AM ET.


Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CME Group Inc.:

  • Recent price target increases from multiple analysts, including Barclays raising it to $257.00, indicate strong market confidence in CME Group Inc.'s growth potential.
  • The stock has shown resilience with a current price of $236.72, reflecting a solid performance despite market fluctuations.
  • Analysts have given CME Group Inc. an average rating of "Hold," suggesting that while there may not be immediate buy signals, the stock is stable and worth monitoring.
  • With a market capitalization of approximately $85.30 billion, CME Group Inc. is a significant player in the financial services sector, providing a level of stability and reliability for investors.
  • Recent upgrades from firms like Citigroup and Piper Sandler, which have set target prices above the current trading price, suggest potential for future gains.

CME Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CME Group Inc. for these reasons:

  • Despite recent upgrades, four analysts have rated the stock with a sell rating, indicating some skepticism about its short-term performance.
  • The stock has experienced a decline of 1.1% recently, which may signal underlying weaknesses or market concerns.
  • Insider selling activity, with directors selling shares at prices around $222.92 and $226.96, could indicate a lack of confidence in the stock's near-term prospects.
  • The average target price from analysts is $224.47, which is below the current trading price, suggesting limited upside potential in the near term.
  • The company's price-to-earnings ratio of 25.17 may be considered high, indicating that the stock could be overvalued compared to its earnings, which might deter value-focused investors.

CME Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $226.20, with a high forecast of $258.00 and a low forecast of $180.00.

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 4 sell ratings, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.

According to analysts, CME Group's stock has a predicted downside of -4.15% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 1 downgrade by analysts.

Analysts like CME Group less than other "finance" companies. The consensus rating score for CME Group is 2.00 while the average consensus rating score for "finance" companies is 2.49. Learn more on how CME compares to other companies.


This page (NASDAQ:CME) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners